Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study
Full data from GLAGOV imaging study shows value of driving LDL below 60 mg/dL and presents no red flags for outcomes data due in first quarter of 2017.
You may also be interested in...
Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.
Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.
Positive results in GLAGOV lift PCSK9 inhibitor Repatha, but most likely are still not enough to get rid of reimbursement restrictions for the class, analysts say.